

# EUCAST uudised

EUCAST Eesti esindaja

Marina Ivanova

27.03.2025

Pärnu

# EUCAST Eesti esindaja

- ELMÜ mikrobioloogia sektsioon täidab NAC (*National Antimicrobial Susceptibility Testing Committee*)
- Alates 2010.a. on Eesti läinud üle EUCAST-ile vähemalt humaanmeditsiinis ja Marina Ivanova on Eesti esindaja EUCAST-is (*General Committee member*)
- ELMÜ toetab EUCAST esindaja tegevust läbi ESCMID/ECMMID osalemise toetamise, selle raames toimub EUCAST General Committee iga-aastane koosolek. Kas sel aastal toimub koosolek ESCMID Global raames Viinis
- Võib-olla peame valima uut esindajat? Millised arvamused?

# EUCAST olulisemad uudised

- BP *table* 2025:
  - Breakpoints for endocarditis and meningitis are listed on separate lines only when they differ from the general breakpoints
  - *Streptococcus* groups A, B, C and G Revised breakpoints, Benzylpenicillin (MIC and zone diameter), VITEK-i kasutajad!
  - Mitmed teised BP revideeritud
  - *Viridans* streptokokid ja penitsilliinid (penicillin G, ampicillin) – erinevused endokardiidi ja mitte-endokardiidi BP väärtustel, lisaks veel eraldi väärtus kombineeritud ravi jaoks penicillin G korral
  - *Clostridioides difficile* – fidaxomycin MIK väärtused

# Endokardiidi *breakpoints* – *Viridans streptokokid*

Penicillins	MIC breakpoints (mg/L)			Disk content (µg)	Zone diameter breakpoints (mm)		
	S ≤	R >	ATU		S ≥	R <	ATU
Benzylicillin (screen only)	0.25 <sup>1</sup>	0.25 <sup>1</sup>		1 unit	21 <sup>A</sup>	21 <sup>A</sup>	
Benzylicillin (indications other than endocarditis)	0.25	1		1 unit	21	12	
Benzylicillin (endocarditis)	0.25	0.25			21	21	
Benzylicillin (endocarditis, in combination with other antimicrobial treatment)	(1) <sup>2</sup>	(1) <sup>2</sup>			(12) <sup>B</sup>	(12) <sup>B</sup>	
Ampicillin (indications other than endocarditis)	0.5	2		2	21	15	
Ampicillin iv (endocarditis)	0.5	0.5		2	21	21	
Ampicillin-sulbactam <sup>3</sup>	Note <sup>1,4</sup>	Note <sup>1,4</sup>			Note <sup>A,C</sup>	Note <sup>A,C</sup>	
Amoxicillin (indications other than endocarditis)	0.5	2			Note <sup>A,C</sup>	Note <sup>A,C</sup>	
Amoxicillin iv (endocarditis)	0.5	0.5			Note <sup>A,D</sup>	Note <sup>A,D</sup>	

# EUCAST olulisemad uudised

- When there are no breakpoints in breakpoint tables? September 2024
- EUCAST guidance on Interpretation of MICs for rare yeast without breakpoints in breakpoint tables, 2024-06-19
- Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST procedures, Version 5.0, valid from 2024-12-02
- Guidance Document on Cephalosporins for *Staphylococcus aureus* Infection, 24 February 2025
- Guidance Document on *Stenotrophomonas maltophilia*, Version 2, November 2024
- EUCAST guidance document on Infective Endocarditis: Reporting of antimicrobial susceptibility testing results, December 2024

# Expert rules

- *Enterobacter* spp., *K. aerogenes*, *Citrobacter freundii*, *Hafnia alvei*
- cefotaxime, ceftriaxone, ceftazidime cefotaxime, ceftriaxone, ceftazidime, piperacillin±tazobactam
- IF susceptible *in vitro* to cefotaxime, ceftriaxone, ceftazidime, or **piperacillin±tazobactam** THEN EITHER add a note that monotherapy with cefotaxime, ceftriaxone, ceftazidime or **piperacillin±tazobactam** as well as combination therapy of these agents with an aminoglycoside should be discouraged owing to risk of selecting resistance OR suppress the susceptibility testing results for these agents
- **Maillard et al 2023**

# EUCAST hoiatused – *S. pneumoniae*

- Available gradient tests (Etest™ and MTS™) systematically underestimate benzylpenicillin MIC values in *S. pneumoniae*. This is especially detrimental in the important area close to the R breakpoint.
- Laboratories using gradient tests must be aware of this and MIC values of 0.5 - 2 mg/L should be checked with broth microdilution.
- A beta-lactam intended for use in meningitis should always be tested using broth microdilution if the oxacillin screen is positive.

# EUCAST hoiatused - Enterococcus

- Vancomycin susceptibility testing in *Enterococcus faecalis* and *E. faecium* using MIC gradient tests – a modified warning 21 May, 2019.
- Original warning was issued 10 July, 2018, against the use of gradient tests for the detection of vanB-positive Enterococci.
- Several studies (Norwegian Reference Laboratory, Tromsø, Norway; The EUCAST Development Laboratory, Växjö, Sweden; Robert Koch Institute, Wernigerode, Germany) show that the use of MIC gradient tests with standard inoculum and incubation fail to detect glycopeptide resistance in low-level resistant enterococci (see posters 1754 and 1764, ECCMID 2019). Confirmation of suspected vancomycin resistance with gradient tests, can be significantly improved by the use of a macro method (BHI-medium, McF 2.0 and 48 hours incubation; see poster 1764, ECCMID 2019).
- Uncertain results should be confirmed with a molecular test for vanA and vanB.



# EUCAST koduleht

- Oluline LIS IT tugi – pidevalt vaja via sisse korrekture
- LOINC taotlused (nt cloxacillin)
- RAST tulemuste kajastamine ja LOINC kodeerimine
- Intrinsic resistance programmeerimine LIS-is
- jne